Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

NCT07227350 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT07227350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
February 28, 2031
Enrollment
180 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced basal cell carcinoma